Department of Molecular Genetics, Function and Therapy, The Cyprus Institute of Neurology and Genetics, PO Box 23462, 1683 Nicosia, Cyprus.
Biol Cell. 2010 Jul 23;102(9):515-23. doi: 10.1042/BC20100040.
DM1 (myotonic dystrophy type I) is a common form of muscular dystrophy that affects mainly adults. It is a disease that belongs to the group of defective RNA export diseases, since a major part of the pathogenic mechanism of the disease is the retention of the mutant transcripts in the cell nucleus. The presence of an expanded CUG trinucleotide repeat in the 3'-UTR (3'-untranslated region) of the DMPK (myotonic dystrophy protein kinase) gene causes the attraction of RNA-binding proteins by the nuclear-located mutant transcripts. As a result of the occupation of the RNA-binding proteins, there is defective mis-splicing of several cellular transcripts. This is believed to be a major pathogenic mechanism of the disease and any attempt to repair the activities of the RNA-binding proteins or target the mutant transcripts should be beneficial for the patients. Certain approaches have been described in the literature and they demonstrate progress in various directions. The purpose of the present review is to summarize the successful attempts to tackle the pathogenesis caused by nuclear retention of mutant transcripts in myotonic dystrophy and to discuss the possible gains from such approaches.
DM1(肌强直性营养不良症 I 型)是一种常见的肌肉疾病,主要影响成年人。它属于 RNA 输出缺陷疾病的一种,因为该疾病的发病机制主要是由于突变转录本在细胞核内滞留。在 DMPK(肌强直性营养不良蛋白激酶)基因的 3'-UTR(3'-非翻译区)中存在扩展的 CUG 三核苷酸重复序列,导致 RNA 结合蛋白被吸引到核内的突变转录本上。由于 RNA 结合蛋白的占据,导致几个细胞转录物的剪接异常。这被认为是该疾病的主要发病机制,任何修复 RNA 结合蛋白活性或靶向突变转录本的尝试都应该对患者有益。文献中已经描述了某些方法,并展示了在各个方向上的进展。本综述的目的是总结在肌强直性营养不良症中核内滞留的突变转录本引起的发病机制的成功尝试,并讨论这些方法可能带来的益处。